Utilization Trend of Parenteral Antidiabetic Drugs in Type 2 Diabetic Patients Covered by Iran Health Insurance Organization from 2011 to 2030

Background: Exploring and analyzing the cost of medicines is an important tool for their management and planning. This study aims to analyze the utilization and costs of parenteral anti-diabetic medications during the past decade and predict the future trend of these medications from 2021 to 2031 in people that are covered by Iran Health Insurance Organization (IHIO). Methods: This study was based on secondary analysis of data routinely reported to IHIO from 2011 to 2019. For each drug, the Defined Daily Dose (DDDs) and DDDs per 1000 inhabitants per day were calculated for the last 9 years according to the WHO protocol. Then a regression analysis was used to predict the utilization trend of each drug for the following 10 years. Results: The overall utilization of injectable antidiabetic drugs has constantly increased during the last nine years. This increasing trend is estimated to continue during the next decade. Conclusion: In Iran, the increase in the diabetic population and better access in the future will be the main reasons for the increase in the utilization of various insulins. The increasing trend of utilizing injectable anti-diabetic drugs in Iran might be partly due to new patients and partly because of improvement in patient access to new treatments. This also suggests that, compared to the average in the commonwealth countries, Iranian diabetic patients has faced lack of drug utilization in the past decade that is gradually reducing.

[1]  M. Mortensen,et al.  Trends in antidiabetic drug utilization and expenditure in Denmark: A 22‐year nationwide study , 2020, Diabetes, obesity & metabolism.

[2]  A. Alsayyad,et al.  Type 2 diabetes and healthcare resource utilisation in the Kingdom of Bahrain , 2019, BMC Health Services Research.

[3]  H. Ebrahimi,et al.  Insulin pen use and diabetes treatment goals: A study from Iran STEPS 2016 survey , 2019, PloS one.

[4]  Shih-Yi Lin,et al.  Trends in antidiabetic medical treatment from 2005 to 2014 in Taiwan. , 2019, Journal of the Formosan Medical Association = Taiwan yi zhi.

[5]  Ali Ardalan,et al.  Iran in transition , 2019, The Lancet.

[6]  J. Mbanya,et al.  Economic Impact of Diabetes in Africa , 2019, Current Diabetes Reports.

[7]  T. Maljanen,et al.  Growth of diabetes drug expenditure decomposed-A nationwide analysis. , 2018, Health policy.

[8]  Antonio Ramírez de Arellano,et al.  The Economic Burden of Insulin-Related Hypoglycemia in Spain , 2017, Diabetes Therapy.

[9]  B. Wettermark,et al.  Drug Utilization Research: Methods and Applications , 2016 .

[10]  K. Taxis,et al.  Introduction to drug utilization research , 2016 .

[11]  H. Ou,et al.  Recent trends in the use of antidiabetic medications from 2008 to 2013: A nation‐wide population‐based study from Taiwan , 2016, Journal of diabetes.

[12]  A. Rashidian,et al.  Low utilisation of diabetes medicines in Iran, despite their affordability (2000–2012): a time-series and benchmarking study , 2014, BMJ Open.

[13]  H. Wee,et al.  Adherence to premixed insulin in a prefilled pen compared with a vial/syringe in people with diabetes in Singapore. , 2014, Clinical therapeutics.

[14]  D. Wysowski,et al.  Use of Antidiabetic Drugs in the U.S., 2003–2012 , 2014, Diabetes Care.

[15]  M. Javanbakht,et al.  Cost-of-Illness Analysis of Type 2 Diabetes Mellitus in Iran , 2011, PloS one.

[16]  D. Wysowski,et al.  Use of Antidiabetic Drugs in the , 2014 .

[17]  R. Henry,et al.  Diagnosis and Management of Type 2 Diabetes , 2011 .